Ascentage Pharma, Takeda and IPO
The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...
Venture Global launched its initial public offering with a lofty goal: Raise up to $2.3 billion at a $110 billion valuation ...
The year 2025 is expected to see a resurgence of IPOs due to policy changes, monetary easing, and a favorable business ...
In 2024, global and US markets saw a slight increase in IPOs. Syntax Data used its FIS classification system to analyze the ...
After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...
Denta Water received strong demand from across investor categories, oversubscribing by a massive 221.68x. Institutional and ...
Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...
When Donald Trump’s real estate business wanted to break into the Indian market in 2012, it turned to Atul Chordia and his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback